Methods and compositions for targeting compounds to muscle

Details Methods and compositions for targeting compounds to muscle Methods and compositions for targeting compounds to muscle

1998-05-26

2001-12-11

Carlson, Karen Cochrane (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

6 to 7 amino acid residues in defined sequence

C530S328000, C530S327000, C530S326000, C530S300000

Reexamination Certificate

active

06329501

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to methods for gene therapy, particularly for targeting genes, proteins, pharmaceuticals, or other compounds to muscle.
BACKGROUND OF THE INVENTION
The capabilities to introduce a particular foreign or native gene sequence into a mammal and to control the expression of that gene are of substantial value in the fields of medical and biological research. Such capabilities provide a means for studying gene regulation and for designing a therapeutic basis for the treatment of disease.
In addition to introducing the gene into mammals, providing expression of the gene at the site of interest remains a challenge. Methods have been developed to deliver DNA to target cells by capitalizing on indigenous cellular pathways of macromolecular transport. In this regard, gene transfer has been accomplished via the receptor-mediated encytosis pathway employing molecular conjugate vectors.
Inherited diseases of muscle pose a therapeutic challenge, as muscle is the single largest tissue of the body. Pharmacologic approaches do not significantly alter the course of many of these diseases as such approaches fail to correct the underlying genetic deficit. New approaches, relying on the transfer of genetic material have been advocated. However, current methodologies used for gene therapy are limited in their usefulness with regard to treating myopathies. Local administration of gene therapy vectors or transplantation of donor cells only treat the immediate area of the injection site. Effective therapy with these methods requires multiple injections and carry the safety risks associated with disease transplantation and the use of immunosuppressive drugs.
Duchenne muscular dystrophy is probably the most common inherited progressive lethal disorder of mankind. The rate of occurrence of the disease is attributable to the very high mutation rate of the gene. The progression of the clinical disease is characterized by skeletal muscle tissue deterioration and wasting. Duchenne muscular dystrophy (DMD) follows a degenerative course which confines sufferers to a wheelchair by the age of about 12 years old and results in death by the third decade due to cardiac or respiratory failure.
DMD results from mutations, mainly frame-shift deletions, in a single, recessively inherited gene. The gene has been cloned and represents the largest gene so far identified in the human genome, spanning at least 2.3 megabases in the short arm of the X chromosome.
Positional cloning of the X-linked gene has revealed that defects of the dystrophin gene lead to either Duchenne or Becker muscular dystrophy (BMD). The 14 kilobase (kb) dystrophin mRNA encodes a 3685 amino acid protein of 427 kilodaltons (kD) with overall similarity to the cytoskeletal proteins &bgr;-spectrin and &agr;-actinin. These proteins perform structural roles in static and dynamic cellular processes and all cell types. Dystrophin is associated with the cytoplasmic face of the sarcolemma and is thus an essential component of the muscle cytoskeleton. Although the exact function of dystrophin is unknown, it has been postulated to contribute to stabilization of the sarcolemma.
The current approaches to the in vivo transfer of dystrophin cDNA for the treatment of DMD have involved direct intramuscular injection of naked plasmid DNA or recombinant viral vectors. However, these techniques suffer from the limitation that skeletal muscle comprises a large proportion of the cells of the body, making widespread intramuscular transduction impractical in a clinical context. Furthermore, some muscles affected in DMD, such as the heart and diaphragm, are not readily accessable to direct injection.
Current approaches to gene therapy in inherited myopathies are limited in practicality either by the mode of administration or the capacity of the vector used for gene transfer. Therefore, methods are needed for targeting specific compositions to muscle cells.
SUMMARY OF THE INVENTION
Compositions and methods for targeting genes, proteins, pharmaceuticals, or other compounds to muscle are provided. The compositions comprise peptide sequences which bind muscle, in vivo, with high specificity. Both species-specific and species-independent sequences have been determined.
The compositions are useful in gene therapy methods for the treatment of myopathies, gene therapy of disease where muscles potentially serve as reservoirs of protein production, and delivery of a wide variety of drugs to muscles.


REFERENCES:
patent: 4879216 (1989-11-01), Hallermayer et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5846773 (1998-12-01), Lee et al.
Beri et al. (1987; Nucleic Acids Res. 15:7991-8001).*
Yamamoto et al. (1996; DNA Res. 3:257-262).*
PCT International Search Report, PCT/US98/10815, dated Sep. 28, 1998.
Pasqualini et al. (Mar. 28, 1996), “Organ Targeting In Vivo Using Phage Display Peptide Libraries”,Nature 380: 364-366.
Feero et al. (Feb. 1996), “Toward Systemic Gene Delivery For Duchenne Muscular Dystrophy: Transferrin As A Muscle Targeting Ligand”,Neurology 46(2):A390, S42.003.
Cruz et al. (1985), “Conus Geographus Toxins That Discriminate Between Neuronal and Muscle Sodium Channels”,The Journal of Biological Chemistry 260(16):9280-9288.
Russell (Mar. 1996), “Peptide-Displaying Phages For Targeted Gene Delivery”,Nature Medicine 2(3):276-277.
Barry et al. (Mar. 1996), “Toward Cell-Targeting Gene Therapy Vectors: Selection of Cell-Binding Peptides From Random Peptide-Presenting Phage Libraries”,Nature Medicine 2(3):299-305.
Polgren et al. (1997), “Identification of Muscle Homing Sequences By Using Phage Display Libraries of Peptides”,Tumor Biology 18(Supplement 1):77.
Schumacher et al. (Mar. 1996), “Identification of D-Peptide Ligands Through Mirror-Image Phage Display”,Science 271:1854-1857.
Cwirla et al. (1990), “Peptides On Phage: A Vast Library Of Peptides For Identifying Ligands”,Proc. Nat'l Acad. Sci. USA 87:6378-6382.
Wu et al. (1991), “Receptor-Mediated Gene Delivery In Vivo”,The Journal of Biological Chemistry 266(22):14338-14342.
Wu et al. (1988), “Receptor-Mediated Gene Delivery and Expression In Vivo”,The Journal of Biological Chemistry263(29):14621-14624.
Wu et al. (1989), “Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements In Vivo”,The Journal of Biological Chemistry 264(29):16985-16987.
Zenke et al. (1990), “Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way To Introduce DNA Into Hematopoietic Cells”,Proc. Nat'l Acad. Sci. USA 87:3655-3659.
Wagner et al. (1990), “Transferrin-Polycation Conjugates As Carriers For DNA Uptake Into Cells”,Proc. Nat'l Acad. Sci. USA 87:3410-3414.
Barr et al. (1991), “Systemic Delivery of Recombinant Proteins By Genetically Modified Myoblasts”,Science 254:1507-1509.
Velez-Yanguas et al. (1996), “The Evolution of Chemotherapeutic Agents for the Treatment of Pediatric Musculoskeletal Malignancies”,The Orthopedic Clinics of North America 27(3):545-549.
Douglas et al. (1995), “Targeted Gene Therapy”,Tumor Targeting 1(2):67-84.
Le Bricon et al. (1995), “Negative Impact of Cancer Chemotherapy on Protein Metabolism in Healthy and Tumor-Bearing Rats”,Metabolism 44(10):1340-1348.
England et al. (1990), “Very Mild Muscular Dystrophy Associated With the Deletion of 46% of Dystrophin”,Nature 343(6254):180-182.
Haeckher et al. (1996), “In Vivo Expression of Full-Length Human Dystrophin From Adenoviral Vectors Deleted of All Viral Genes”,Human Gene Therapy 7:1907-1914.
Devlin et al. (1990), “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”,Science 249:404-406.

Affiliated with

Also associated with

Rating

Methods and compositions for targeting compounds to muscle does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for targeting compounds to muscle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for targeting compounds to muscle will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2596900